Payment overview · 2025
General Payments
$1,690.24
37 reported records · 15 companies
Healthcare provider profile · identity verified
Ali A Khan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PIGEON, MI · NPI 1598870503
Verified facts
What the public records show
CMS Open Payments records show Ali A Khan, MD received $1,690.24 in general payments during 2025 across 37 reported records.
ABIOMED accounted for 41.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $699.34 | 41.4% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $261.20 | 15.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $125.00 | 7.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$108.98 | 6.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $82.32 | 4.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $76.99 | 4.5% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $72.35 | 4.3% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $58.78 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.55 | 3.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.34 | 2.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.09 | 2.2% | 2 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $20.77 | 1.2% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.85 | 1.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.54 | 1.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.14 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,690.24 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $154.67 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $140.01 | 3 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $121.19 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $108.98 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $76.99 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $58.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $50.55 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $41.34 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.21 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 96 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
120 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 12 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 18 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 610 | 87 |
| Potassium Chloride | Potassium Chloride | 383 | 66 |
| Eliquis | Apixaban | 380 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 358 | 71 |
| Furosemide | Furosemide | 341 | 54 |
| Losartan Potassium | Losartan Potassium | 339 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 305 | 50 |
| Gabapentin | Gabapentin | 301 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 294 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 255 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 47 |
| Sertraline Hcl | Sertraline Hcl | 176 | 24 |
| Omeprazole | Omeprazole | 154 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 36 |
| Lisinopril | Lisinopril | 148 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 142 | 22 |
| Ozempic | Semaglutide | 139 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 18 |
| Farxiga | Dapagliflozin Propanediol | 120 | 13 |
| Lactulose | Lactulose | 120 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 120 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 119 | 16 |
| Donepezil Hcl | Donepezil Hcl | 117 | 14 |
| Alprazolam | Alprazolam | 116 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 114 | 16 |
| Metformin Hcl | Metformin Hcl | 114 | 27 |
| Xarelto | Rivaroxaban | 107 | 19 |
| Buspirone Hcl | Buspirone Hcl | 103 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 103 | 60 |
| Allopurinol | Allopurinol | 100 | 17 |
| Jardiance | Empagliflozin | 96 | 12 |
| Lorazepam | Lorazepam | 95 | 21 |
| Carvedilol | Carvedilol | 93 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 93 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 92 | 20 |
| Enulose | Lactulose | 91 | 22 |
| Latanoprost | Latanoprost | 89 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 76 | 15 |
| Memantine Hcl | Memantine Hcl | 76 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 24 |
| Montelukast Sodium | Montelukast Sodium | 75 | 17 |
| Spironolactone | Spironolactone | 74 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 11 |
| Glipizide | Glipizide | 71 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | suppressed |
| Prednisone | Prednisone | 68 | 22 |
| Bumetanide | Bumetanide | 67 | 11 |
| Ezetimibe | Ezetimibe | 67 | 14 |
| Levetiracetam | Levetiracetam | 62 | suppressed |
| Risperidone | Risperidone | 62 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 60 | 12 |
| Famotidine | Famotidine | 59 | 16 |
| Mirtazapine | Mirtazapine | 58 | 13 |
| Trazodone Hcl | Trazodone Hcl | 58 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 52 | 38 |
| Ketoconazole | Ketoconazole | 50 | 15 |
| Azithromycin | Azithromycin | 49 | 36 |
| Clonazepam | Clonazepam | 49 | 12 |
| Torsemide | Torsemide | 49 | 12 |
| Celecoxib | Celecoxib | 46 | 19 |
| Cephalexin | Cephalexin | 46 | 23 |
| Morphine Sulfate | Morphine Sulfate | 46 | 13 |
| Timolol Maleate | Timolol Maleate | 46 | suppressed |
| Valsartan | Valsartan | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Metolazone | Metolazone | 45 | suppressed |
| Simvastatin | Simvastatin | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 13 |
| Ondansetron Odt | Ondansetron | 44 | 26 |
| Dexamethasone | Dexamethasone | 42 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 12 |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 37 | suppressed |
| Rexulti | Brexpiprazole | 37 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 35 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 32 | suppressed |
| Fentanyl | Fentanyl | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 31 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Movantik | Naloxegol Oxalate | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Savella | Milnacipran Hcl | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 24 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 23 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 18 |
| Nystatin | Nystatin | 22 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 15 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 19 | suppressed |
| Levemir | Insulin Detemir | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Gentamicin Sulfate | Gentamicin Sulfate | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Topiramate | Topiramate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 14 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Phenytoin | Phenytoin | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Fluorouracil | Fluorouracil | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,690.24 · 37 records | ABIOMED | AIRSUPRA, Auvelity, CHARTIS CATHETER, COREVALVE EVOLUT R, Cologuard Collection Kit, FUROSCIX, JARDIANCE, Kerendia, Korlym, LifeVest, MOUNJARO, Ozempic, PULMONX CHARTIS TABLET CONSOLE, REXULTI, Repatha, Rybelsus, Wegovy, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error